Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

To Ensure Workable Procedures, Consult Your Workers, FDA Advises

This article was originally published in The Silver Sheet

Executive Summary

EFFECTIVE QUALITY SYSTEM PROCEDURES begin with listening to employee feedback, FDA quality systems expert Kim Trautman tells device manufacturers. She points out that some firms have too many procedures, while others stuff their SOPs full of extraneous information, which is why it's important for companies to ask workers to sound the alarm when they become overwhelmed. Managers “need to go to the people who are doing the processes and determine what procedures they're utilizing, how they're utilizing them, and whether [the SOPs] are confusing or bouncing them around to too many different places,” Trautman says. Also, officials at Welch Allyn, Thoratec and Philips Consumer Healthcare Solutions discuss their approaches to building strong SOPs.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036270

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel